Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 4/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.32 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9271489 | 0.89 | SIGMAR1 (0.48) | SIGMAR1CHRNB2CHRNA4TNFCYP19A1 | |
| SCHEMBL30322659 | 0.89 | SIGMAR1 (0.48) | SIGMAR1CHRNB2CHRNA4TNFCYP19A1 | |
| SCHEMBL17264312 | 0.87 | SIGMAR1 (0.40) | SIGMAR1CHRNB2CHRNA4TNFCYP19A1 | |
| SCHEMBL8618246 | 0.84 | SIGMAR1 (0.46) | SIGMAR1CHRNB2CHRNA4TNFCYP19A1 | |
| SCHEMBL30322863 | 0.78 | MAOA (0.47) | SIGMAR1TNFCYP19A1MAOAMAOB | |
| SCHEMBL3075871 | 0.78 | MAOA (0.47) | SIGMAR1TNFCYP19A1MAOAMAOB | |
| SCHEMBL11559098 | 0.77 | MAOA (0.45) | SIGMAR1TNFCYP19A1MAOAMAOB | |
| SCHEMBL14452876 | 0.74 | SIGMAR1 (0.48) | SIGMAR1CHRNB2CHRNA4MAOAMAOB | |
| SCHEMBL29699898 | 0.74 | SIGMAR1 (0.48) | SIGMAR1CHRNB2CHRNA4MAOAMAOB | |
| SCHEMBL17264315 | 0.74 | CHRNB2 (0.37) | SIGMAR1CHRNB2CHRNA4TNFCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850253-B2 | Condensed cyclic compound and organic light emitting device including the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2017-12-26 | — | — | US | disclosed |
| US-20150333271-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2015-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150333271-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME | CRY1, CCNT1, CCNA1 | SIGMAR1 2410/4885CHRNB2 1953/4885CHRNA4 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.